$NUVB News
Last published 2d ago
- 2d agoNUVBNuvation Bio to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...
- 1w agoNUVBNuvation Bio Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoNUVBNuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesPR NewswireNew sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA studyNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company
- 3w agoNUVBNuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PR NewswireNEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will
- 1mo agoNUVBNuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung CancerPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 1mo agoNUVBNuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung CancerPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 2mo agoNUVBNuvation Bio to Participate in Upcoming Investor ConferencesPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 2mo agoNUVBNuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant GliomaPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 3mo agoNUVBNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported...
- 3mo agoNUVBNuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 3mo agoNUVBNuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026PR NewswireNuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,...
- 3mo agoNUVBNuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant GliomaPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 4mo agoNUVBNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes OfferingPR NewswireNuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,...
- 4mo agoNUVBNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United KingdomPR NewswireNuvation Bio (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that...
- 4mo agoNUVBNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesPR NewswireNEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest...
- 4mo agoNUVBNuvation Bio Announces Proposed Convertible Senior Notes OfferingPR NewswireNuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,...
- 5mo agoNUVBNuvation Bio to Present at the Jefferies Global Healthcare ConferencePR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 5mo agoNUVBNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual MeetingPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 6mo agoNUVBNuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung CancerPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 6mo agoNUVBNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced today...
- 6mo agoNUVBNuvation Bio to Participate in Upcoming Investor ConferencesPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 6mo agoNUVBNuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatePR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported...
- 6mo agoNUVBNuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System CancersPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 6mo agoNUVBNuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026PR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 6mo agoNUVBNuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026PR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it ...
- 7mo agoNUVBKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmGlobeNewswireNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE:NUVB) breached their fiduciary duties
- 7mo agoNUVBKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB)...
- 7mo agoNUVBNuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi SankyoPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 7mo agoNUVBEisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyPR NewswireEisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in...
- 8mo agoNUVBNuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026PR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 8mo agoNUVBKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmGlobeNewswireNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE:NUVB) breached their fiduciary duties
- 8mo agoNUVBKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB)...
- 8mo agoNUVBNuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported...
- 8mo agoNUVBNuvation Bio to Participate in Upcoming Investor ConferencesPR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...
- 8mo agoNUVBNuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026PR NewswireNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it ...
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 9mo agoNUVBNuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant GliomaBusiness WireProtocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now complete The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance
- 10mo agoNUVBNuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and JapanBusiness WireStrategic collaboration expands taletrectinib global reach with a leading oncology partner Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of
- 10mo agoNUVBNuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireNuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of
- 11mo agoNUVBInnovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug ListPR NewswireInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...
- 11mo agoNUVBNuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-OncologyBusiness WireSafusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions with FDA where alignment was reached on modifying
- 11mo agoNUVBNuvation Bio to Participate in Upcoming Investor ConferencesBusiness WireNuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of
- 1y agoNUVBNuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness WireSuccessfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small
- 1y agoNUVBNuvation Bio to Participate in Upcoming Investor ConferencesBusiness WireNuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of
- 1y agoNUVBNuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant GliomaBusiness WireNo targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Nuvation
- 1y agoNUVBNuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025Business WireNuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025,
- 1y agoESRTNUVBNYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall StreetPR NewswireThe New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for ...
- 1y agoNUVBNuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung CancerBusiness WireTrial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer Nuvation Bio Inc. (NYSE:NUVB), a global oncology company
- 1y agoNUVBNuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung CancerBusiness WireIBTROZI will be marketed in Japan by Nippon Kayaku Approval is based on the pivotal Phase 2 TRUST studies, demonstrating IBTROZI's high rates and durability of responses Primary companion diagnostic approved in